TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00987857

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2 yearly endoscopy
Description: 2 yearly endoscopy versus endoscopy at need

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2 yearly endoscopy
Description: 2 yearly endoscopy versus endoscopy at need

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: comparison of screening methods
Description: 2 yearly endoscopy versus endoscopy at need

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: comparison of screening methods
Description: 2 yearly endoscopy versus endoscopy at need

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: diagnostic endoscopic procedure
Description: 2 yearly endoscopy versus endoscopy at need
Study: NCT01939587

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01605084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Oral, Two 400 mg Tablets, Once daily (QD), 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Tablet, Oral, 100 mg, Once daily (QD), 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Tablet, Oral, 100 mg, Once daily (QD), 48 weeks
Study: NCT00308711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal insert 100 mcg
Description: Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal insert 50 mcg
Description: Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone vaginal insert (Cervidil)
Description: Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
Study: NCT01605084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized NRTI backbone
Description: tablet/capsule, Noninvestigational products i.e. NRTI backbone will be administered according to their respective package inserts for 48 weeks~NRTI backbone are:~- Abacavir (300 mg), Tenofovir (300 mg), Didanosine (250 mg or 400 mg), Stavudine (30 mg or 40 mg), Emtricitabine (200 mg), Lamivudine (300 mg), Zidovudine (300 mg), EPZICOM® (600 mg Ziagen® + 300 mg Lamivudine), COMBIVIR® (150 mg Lamivudine + 300 mg Zidovudine)~The following NRTI combinations are prohibited in this study:~* Didanosine + Stavudine~* Zidovudine + Stavudine~* Lamivudine + Emtricitabine
Study: NCT03149237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples-based services
Description: Couples-based services, including treatment, counseling and peer mentoring in the community.
Study: NCT02366078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART
Description: Paced breathing meditation with cognitive training
Study: NCT03500328

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Natalizumab, Alemtuzumab, Ocrelizumab, Rituximab, Cladribine, Ofatumumab, Ublituximab-xiiy
Description: Early Aggressive Therapy
Study: NCT02955225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Moticon OpenGO insole
Description: A Moticon OpenGO insole measures shoe pressure and connects/sends data to a ANT+ enabled smartphone.
Study: NCT00145574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colesevelam HCl
Description: Tablets
Study: NCT00987857

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diagnostic endoscopic procedure
Description: 2 yearly endoscopy versus endoscopy at need

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic biopsy
Description: 2 yearly endoscopy versus endoscopy at need

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic biopsy
Description: 2 yearly endoscopy versus endoscopy at need

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic procedure
Description: 2 yearly endoscopy versus endoscopy at need

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic procedure
Description: 2 yearly endoscopy versus endoscopy at need

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: QOL aims to elicit any differences in QOL between 2 yearly endoscopy versus endoscopy at need

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: QOL aims to elicit any differences in QOL between 2 yearly endoscopy versus endoscopy at need

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: screening method
Description: All Barretts patients to be screened

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: screening method
Description: All Barretts patients to be screened
Study: NCT03718624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: apatinib：500mg qd po, 28 days is a cycle. preoperative 2 cycles, 2 cycles after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel: intraperitoneal paclitaxel 20 mg/m2 and intravenous paclitaxel 50 mg/m2 on days 1 and 8 ，21 days is a cycle. preoperative 3 cycles, 3 cycles after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1： According to the body surface area, BSA \<1.25m2，40mg bid; 1.25m2≤BSA≤1.5m2，50mg bid; BSA \>1.5m2, 60mg bid. Take the medicine twice daily for 2 weeks, then suspend for 1 week. preoperative 3 cycles, 3 cycles after surgery.
Study: NCT02574429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: Cognitive Processing Therapy is an evidenced-based treatment for PTSD. The investigators are offering CPT group over 13 weeks (12 group sessions \& 1 individual session). CPT focuses on challenging beliefs that developed or were reinforced following the trauma(s).
Study: NCT04335929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behavior Therapy
Description: The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
Study: NCT00145574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colesevelam HCl
Description: Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching Tablets
Study: NCT00958165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioFocus EAS-AC
Description: PVI for PAF
Study: NCT01504685

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Banded Laparoscopic Roux-en-Y gastric bypass
Description: A 6.5-cm polypropylene Marlex mesh was placed immediately cephalad to the gastrojejunostomy. The gastrojejunostomy was hand-sewn in 2 layers using 3-0 Polyglactin for the internal and 3-0 silk for the external layer.~The length of alimentary and biliopancreatic limbs was approximately 150 cm and 50 cm, respectively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unbanded Laparoscopic Roux- en-Y gastric bypass
Description: A hand-sewn gastrojejunostomy in 2 layers using 3-0 Polyglactin for the internal and 3-0 silk for the external layer.~To ensure a diameter of 1-1.5 cm,a 32F bougie was used to calibrate the gastro jejunum anastomosis. The length of alimentary and biliopancreatic limbs was approximately 150 cm and 50 cm, respectively.
Study: NCT03851198

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care or Usual Clinical Practice
Description: The guidelines for the management according to the mild cognitive impairment in primary care will be the treatment guidelines for the Standard Care.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Care or Usual Clinical Practice
Description: The guidelines for the management according to the mild cognitive impairment in primary care will be the treatment guidelines for the Standard Care.
Study: NCT01882530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Study: NCT01516463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Collagenase Santyl
Description: Applied topically (2 mm thickness once daily)

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Bacitracin
Description: Applied topically (2 mm thickness) once daily
Study: NCT03296449

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: A recruitment maneuver will be applied to the ventilated lung. Immediately continuous positive airway pressure, at a pressure of 2-3cmH2O will applied to the non-ventilated lung for 20 minutes by the Mallinckrodt Bronchocath Disposable CPAP system (a recognised anesthetic breathing system design for CPAP).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HFJV
Description: A recruitment maneuver will be applied to the ventilated lung. Immediately, high-frequency jet ventilation, with a driving pressure of 0.5 atm and a respiratory rate of 100 cycles per minute will applied to the non-ventilated lung for 20 minutes using the Monsoone III Jet Ventilator (Acutronic, Hirzel, Switzerland). Monsoone III is a recognised ventilator design for HFJV.
Study: NCT03776591

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right colectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right colectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central lymphadenectomy and vascular ligation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central lymphadenectomy and vascular ligation
Study: NCT02601833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: No caries removal will take place. The tooth will be dried and Silver Diamine Fluoride will be placed on the carious dentin until saturated. Excess will be blotted dry with a cotton pellet.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Caries Management
Description: These children will receive restorative dental care in alignment with the American Academy of Pediatric Dentistry guidelines, within the confines of the Mott Children's Health Center clinic. This treatment typically includes administration of local anesthesia, placement of rubber dam, caries removal with rotary and hand instruments, and placement of a final restoration.
Study: NCT01154426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study: NCT03189680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: 3-week-long intervention, administered daily, targeted postural instability and mobility using at-limit intensity sensorimotor and visuomotor agility training
Study: NCT03500328

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
Description: Traditional Therapy
Study: NCT02069522

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Milk-based Formula Containing Carotenoid
Description: Fed ad libitum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational Milk-based Formula Containing Carotenoid
Description: Fed ad libitum
Study: NCT04334499

Intervention type: OTHER
Intervention: Sample collection from tissue discard
Description: Collection of vitreous humor tissue and venous blood from subjects undergoing ocular surgery that may provide vitreous humor discarded tissue.

Intervention type: OTHER
Intervention: Sample collection from tissue discard
Description: Collection of vitreous humor tissue and venous blood from subjects undergoing ocular surgery that may provide vitreous humor discarded tissue.

Intervention type: OTHER
Intervention: Sample collection from tissue discard
Description: Collection of vitreous humor tissue and venous blood from subjects undergoing ocular surgery that may provide vitreous humor discarded tissue.
Study: NCT02955225

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Passive shoe insole
Description: A deactivated insole measures shoe pressure only.
Study: NCT02109731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative airway pressure delivery
Description: Negative airway pressure delivery (breathing against a vaccuum) in order to improve the tone of the upper airway muscles and make them less susceptible to collapse during sleep.
Study: NCT03924960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: Participants in this group will perform a 20-25 minutes of aerobic exercise with a maximum capacity of 3-4 minutes (HRmax 80-95%) and active recovery for 3-4 minutes (HRmax 30-50%), five exercise sessions per week for 6 weeks.
Study: NCT04334499

Intervention type: OTHER
Intervention: Sample collection from tissue discard
Description: Collection of vitreous humor tissue and venous blood from subjects undergoing ocular surgery that may provide vitreous humor discarded tissue.
Study: NCT01154426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given orally
Study: NCT04686383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAL056 mesylate
Description: Dosage form: 20 mg CAL056 mesylate/tablet
Study: NCT00414388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400mg twice daily
Study: NCT03467425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Description: FF is a dry white powder containing 100 mcg GW685698 blended with lactose in one blister in the first strip of the DPI. UMEC/VI is a dry white powder containing 62.5 mcg of UMEC and 25 mcg of VI per blister, both blended together with lactose and magnesium stearate in the second strip of the DPI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Corticosteroid
Description: Inhaled Corticosteroid (ICS) as prescribed by the physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAMA
Description: LAMA as prescribed by the physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LABA
Description: LABA as prescribed by the physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COPD rescue medications
Description: Rescue medications for COPD will be prescribed and obtained according to usual practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COPD rescue medications
Description: Rescue medications for COPD will be prescribed and obtained according to usual practice.
Study: NCT02153775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: Comparison of progressive muscle relaxation and no intervention (e.g., reading newspaper of the day) for the same amount of time.
Study: NCT04568122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saliva test kit
Description: Kit including tube with closed reagents using loop-mediated isothermal amplification (LAMP) assay to detect SARS-CoV-2 virus.
Study: NCT01243346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib besylate (CP-868,596-26), Dose: 140mg BID
Description: Highly potent inhibitor of both PDGFR receptors alpha and beta
Study: NCT00813358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith TX2® TAA Endovascular Graft
Description: Endovascular treatment with the study device
Study: NCT04044417

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: currettage
Description: open flap debridement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: currettage
Description: open flap debridement
Study: NCT03924960

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-intensity continuous training
Description: Participants in this group will perform a 30-45 minute ergometric cycling exercise at 65-70% of the measured maximum heart rate (HRmax), five exercise sessions per week for 6 weeks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Usual care control group
Study: NCT04044417

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: currettage
Description: open flap debridement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: curcumin simvastatin paste
Description: Curcumin is the primary active constituent of turmeric. Simvastatin is chemical modification of lovastatin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: curcumin simvastatin paste
Description: Curcumin is the primary active constituent of turmeric. Simvastatin is chemical modification of lovastatin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EDTA root conditioning
Description: EDTA is an aminopolycarboxylic acid and a colourless, water-soluble solid
Study: NCT00862784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-1121B (ramucirumab)
Description: 8 milligrams/kilogram (mg/kg) IMC-1121B (ramucirumab) infusions every 2 weeks
Study: NCT01180400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Tablet, oral, twice daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral, twice daily for 8 weeks
Study: NCT04610606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal intervention (MM)
Description: Exercise: Moderate intensity resistance and aerobic exercise, including one weekly supervised session and a home-based program. Participants were asked to 1) accumulate 30 min of aerobic exercise per day of their preferred type (ex. walking) and 2) perform 30 min of resistance exercise targeting major muscle groups, every second day for 2 sets of 8-12 reps.~Nutrition: Optimize diet with protein-rich foods to meet protein intake of \>1.2 g/kg/d and energy of 25-30 kcal/kg/d. The supplement consists of whey protein isolate (with the goal of reaching 1.5 g/kg/d, providing 25 g/meal), 6g of leucine, fruit-flavored fish oil added with vitamin D.~Relaxation strategies: private consultations with psychology-trained personnel whereby techniques aimed at reducing anxiety are practiced. Participants are also provided with a compact disc with relaxation exercises to be used at home 2-3 times per week.
Study: NCT00862784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 milligrams/square meter (mg/m²) intravenous infusion over 2 hours on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: 400 mg/m² intravenous infusion over 2 hours on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 400 mg/m² intravenous bolus injection over 2-4 minutes, immediately following folinic acid infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 2400 mg/m² intravenous continuous infusion over 46 hours immediately following bolus 5-FU on Days 1 and 2
Study: NCT03293537

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Skin conductance and Heart rate measurement
Description: while observing selected photos the Skin conductance and heart rate will be measured.
Study: NCT04209283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visuospatial interference
Description: Behavioral: Brief cognitive intervention. A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game play with mental rotation) with instructions to engage in the task self-guided in the subsequent weeks.
Study: NCT03580603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visualization tool
Description: Visual representation of past microbiological culture data
Study: NCT01941446

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eravacyline, Moxifloxacin, and placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eravacyline, Moxifloxacin, and placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eravacyline, Moxifloxacin, and placebo
Study: NCT03080961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIBLOK barrier cream
Description: VIBLOK safety and performance has not been proven yet in humans with an HSV-2 infection.